Thursday 16 October, 2025
Objectives: Crenezumab is an antibody to treat Alzheimer’s Disease (AD). Two Phase 2 studies in mild-to-moderate AD patients evaluated a high…
Read morePoster: Drug/Disease Modelling - CNS
Population pharmacokinetic analysis of Satralizumab in NMOSD patients and healthy volunteers.
Thursday 16 October, 2025
Objectives: Interleukin-6 (IL-6) has been implicated in the immunopathology of neuromyelitis optica spectrum disorder (NMOSD). Satralizumab is a subcutaneously (SC)…
Read moreModel-based meta-analysis of aggregate data on Parkinson’s disease clinical scores to inform future trial design
Thursday 16 October, 2025
Objectives: There is a dire need to develop drugs that modify the progression of Parkinson’s disease (PD). Differentiation of disease…
Read moreSample size for detection of drug effect using item level and total score models for Unified Parkinson’s Disease Rating Scale data
Thursday 16 October, 2025
Objectives: The aim of this investigation was to estimate the sample size required to reach 80% power for detection of…
Read morePlacebo and drug response assessment on Unified Parkinson’s Disease Rating Scale using longitudinal Item Response Modelling
Thursday 16 October, 2025
Objectives: To employ an Item Response Model (IRM) to describe the time course and drug effect in advanced Parkinson’s disease…
Read moreClosed-loop control for propofol administration during anesthesia based on real-time concentration measurement: a simulation study
Thursday 16 October, 2025
Objectives: Propofol administration through open-loop target controlled infusion (TCI) devices is largely used in clinical practice to induce and maintain…
Read moreQuantifying natural amyloid plaque accumulation using ADNI, BIOFINDER, A4 and LEARN datasets
Thursday 16 October, 2025
BackgroundBrain β-amyloid neuritic plaque accumulation is associated with an increased risk of progression to Alzheimer’s disease (AD). Several studies estimate…
Read moreJoint Exposure-Response Analysis of PET Amyloid Plaque Data from the BACE1 Inhibitor Verubecestat and Amyloid mAbs Trials Enhances the Understanding of Drug Effects
Thursday 16 October, 2025
Introduction: Positron-emission tomography (PET) using amyloid radiotracers allows the quantification of pathological amyloid deposition in brain tissues. An exposure-response (E-R)…
Read moreLeiCNS-PK3.2: A Physiologically Based Pharmacokinetic Model Incorporating Active Brain Membrane Transport—Insights into Intracellular Exposure of Acyclovir and Ganciclovir Active Metabolites
Thursday 16 October, 2025
I. Introduction/Objectives Central nervous system (CNS) physiologically based pharmacokinetic (PBPK) models are valuable tools for studying CNS drug distribution. LeiCNS-PK3.0…
Read moreConfirming pharmacokinetic properties of satralizumab using a bodyweight tiered dosing regimen in LUMINESCE, a phase 3 study for generalized Myasthenia Gravis
Thursday 16 October, 2025
Objective: Satralizumab (SA) is a humanized IgG2 monoclonal recycling IL-6 receptor antagonist antibody. It has been approved for treatment of…
Read more